• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    5/8/24 4:31:13 PM ET
    $AIH
    $ALZN
    $CDXC
    $CTMX
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIH alert in real time by email

    Gainers

    • CytomX Therapeutics (NASDAQ:CTMX) stock increased by 87.1% to $7.84 during Wednesday's after-market session. The market value of their outstanding shares is at $534.1 million. As per the press release, Q1 earnings came out today.
    • ZimVie (NASDAQ:ZIMV) shares increased by 17.03% to $18.0. The company's market cap stands at $489.9 million. The company's, Q1 earnings came out today.
    • Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 15.0% to $0.53. The market value of their outstanding shares is at $25.2 million.
    • electroCore (NASDAQ:ECOR) shares rose 11.98% to $7.85. The market value of their outstanding shares is at $47.1 million. The company's, Q1 earnings came out today.
    • Ventyx Biosciences (NASDAQ:VTYX) shares rose 10.81% to $4.92. The company's market cap stands at $346.8 million.
    • Alzamend Neuro (NASDAQ:ALZN) stock increased by 9.82% to $0.58. The market value of their outstanding shares is at $3.9 million.

    Losers

    • Etao International Co (NASDAQ:ETAO) shares decreased by 14.1% to $1.64 during Wednesday's after-market session. The market value of their outstanding shares is at $8.4 million.
    • Enhabit (NYSE:EHAB) stock decreased by 13.1% to $8.43. The market value of their outstanding shares is at $422.8 million. As per the press release, Q1 earnings came out today.
    • Myomo (AMEX:MYO) stock decreased by 10.69% to $3.51. The company's market cap stands at $101.0 million. The company's, Q1 earnings came out today.
    • Exact Sciences (NASDAQ:EXAS) shares decreased by 10.11% to $53.47. The market value of their outstanding shares is at $9.8 billion. As per the press release, Q1 earnings came out today.
    • Outset Medical (NASDAQ:OM) shares declined by 8.25% to $3.79. The market value of their outstanding shares is at $195.9 million. As per the press release, Q1 earnings came out today.
    • ChromaDex (NASDAQ:CDXC) shares decreased by 6.79% to $3.57. The market value of their outstanding shares is at $269.6 million. The company's, Q1 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AIH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIH
    $ALZN
    $CDXC
    $CTMX

    CompanyDatePrice TargetRatingAnalyst
    CytomX Therapeutics Inc.
    $CTMX
    3/16/2026$12.00Neutral → Overweight
    Analyst
    Enhabit Inc.
    $EHAB
    3/6/2026$13.80Buy → Hold
    TD Cowen
    Enhabit Inc.
    $EHAB
    1/22/2026$14.00Perform → Outperform
    Oppenheimer
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    Exact Sciences Corporation
    $EXAS
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    Enhabit Inc.
    $EHAB
    1/13/2026$12.00Hold → Buy
    TD Cowen
    Enhabit Inc.
    $EHAB
    1/8/2026$12.00Neutral → Buy
    UBS
    Enhabit Inc.
    $EHAB
    1/7/2026$10.50Hold
    Truist
    More analyst ratings

    $AIH
    $ALZN
    $CDXC
    $CTMX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Getz Heather C bought $13,972 worth of shares (20,000 units at $0.70), increasing direct ownership by 18% to 131,754 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/17/26 5:39:28 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $51,113 worth of shares (72,000 units at $0.71), increasing direct ownership by 15% to 553,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/16/26 6:08:14 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Getz Heather C bought $50,960 worth of shares (70,000 units at $0.73), increasing direct ownership by 168% to 111,754 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    3/12/26 5:18:01 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $AIH
    $ALZN
    $CDXC
    $CTMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lev Joshua S.

    4 - electroCore, Inc. (0001560258) (Issuer)

    4/1/26 4:01:05 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Baranick Brian

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    3/23/26 9:21:24 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form 4 filed by Herriott James

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    3/23/26 9:20:51 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $AIH
    $ALZN
    $CDXC
    $CTMX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD

    ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in Frontiers in Neuroscience titled "Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder: a post-hoc analysis" by Drs. Michael Ament, Peter Staats, Norianne Theresa Ingram, and Emily Leonard, demonstrating the potential benefits of adjunctive non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and comorbid post-traumatic stress disorder (PTSD). The publicat

    4/1/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the "Company"), (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams will join electroCore, effective April 1, 2026, as the Company's VP, Sales, and Michael Fox will join electroCore, effective April 13, 2026, as the Company's Chief Operating Officer. The Compensation Committee of electroCore's Board of Directors granted 30,000 restricted stock units ("RSUs") to Mr. Abrams and 70,000 RSUs to Mr. Fox in connection with the commencement of their employment. The RSUs were granted as an inducement material to their commencement of employment pursuant to NASDAQ Listin

    3/31/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Expands Intellectual Property Portfolio

    ROCKAWAY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the issuance of two new U.S. patents that further bolster the Company's already extensive intellectual property portfolio. These additions underscore electroCore's position as a leader in non-invasive vagus nerve stimulation (nVNS) technology and demonstrate how a nimble small-cap innovator can build one of the most robust patent portfolios in the field. The newly issued patents are: • U.S. Patent No. 12,208,263, entitled "Devices and Methods for Vagal Nerve Stimulation" was issued on January 28, 2026 and covers innovative meth

    3/30/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AIH
    $ALZN
    $CDXC
    $CTMX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CytomX Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00

    3/16/26 11:34:14 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enhabit Inc. downgraded by TD Cowen with a new price target

    TD Cowen downgraded Enhabit Inc. from Buy to Hold and set a new price target of $13.80

    3/6/26 8:25:46 AM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    Enhabit Inc. upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Enhabit Inc. from Perform to Outperform and set a new price target of $14.00

    1/22/26 8:46:17 AM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    $AIH
    $ALZN
    $CDXC
    $CTMX
    SEC Filings

    View All

    SEC Form 15-12G filed by Exact Sciences Corporation

    15-12G - EXACT SCIENCES CORP (0001124140) (Filer)

    4/2/26 6:06:01 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form PREM14A filed by Enhabit Inc.

    PREM14A - Enhabit, Inc. (0001803737) (Filer)

    3/30/26 9:02:50 AM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.

    SCHEDULE 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    3/27/26 11:19:26 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AIH
    $ALZN
    $CDXC
    $CTMX
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Outset Medical Reports Unaudited Fourth Quarter and 2025 Results

    SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2025, and named Karen N. Prange to its board of directors. Unaudited Fourth Quarter and 2025 Results Revenue in the fourth quarter totaled approximately $28.9 million, bringing revenue for 2025 to approximately $119.5 million, a 5% increase over $113.7 million in 2024.Exiting 2025, more than 1,000 sites of care have insourced dialysis with Outset, performing roughly 1 million treatments per year and more t

    1/12/26 8:30:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $AIH
    $ALZN
    $CDXC
    $CTMX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Stock Movement: Insider Purchase at electroCore Inc. on Jun 6

    **Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report

    6/10/24 12:57:57 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AIH
    $ALZN
    $CDXC
    $CTMX
    Financials

    Live finance-specific insights

    View All

    electroCore Announces Full Year 2025 Financial Results and Organizational Changes

    Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results. Reported record full year of 2025 revenue of $32.0 million, an increase of a

    3/19/26 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

    - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to host conference call today at 8 a.m. ET / 5 a.m. PT - SOUTH SAN FRANCISCO, Calif., M

    3/16/26 7:05:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

    - Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted for mid-year with goal to align on potential registrational trial design in late-line colorectal cancer (CRC) - - Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Conference call on Monday, March 16 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics

    3/16/26 7:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $ALZN
    $CDXC
    $CTMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Enhabit Inc.

    SC 13G - Enhabit, Inc. (0001803737) (Subject)

    11/14/24 9:12:39 PM ET
    $EHAB
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:26:32 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care